Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kymera Therapeutics Inc
(NQ:
KYMR
)
48.56
-0.91 (-1.84%)
Streaming Delayed Price
Updated: 3:49 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kymera Therapeutics Inc
< Previous
1
2
3
4
Next >
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate
September 15, 2022
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).
Via
Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
September 02, 2022
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26...
Via
Benzinga
Where Kymera Therapeutics Stands With Analysts
August 29, 2022
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
August 24, 2022
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
Kymera Therapeutics Stock Scores Rising Relative Price Strength
August 22, 2022
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.
Via
Investor's Business Daily
5 Analysts Have This to Say About Kymera Therapeutics
August 10, 2022
Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Kymera Therapeutics
June 01, 2022
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Kymera Therapeutics Shares Are Falling Today
May 03, 2022
Via
Benzinga
Kymera Therapeutics: Q1 Earnings Insights
May 03, 2022
Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
August 15, 2022
Via
Benzinga
Kymera Therapeutics: Q2 Earnings Insights
August 09, 2022
Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
Analyst Ratings for Kymera Therapeutics
April 28, 2022
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
July 20, 2022
Upgrades
Via
Benzinga
Kymera Therapeutics Commences Initial-Stage Oncology Trials
June 15, 2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.
Via
Benzinga
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
June 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Kymera Therapeutics Stock Is Gaining Wednesday
June 01, 2022
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell...
Via
Benzinga
Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying
June 01, 2022
Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades.
Via
Benzinga
3 Biotech Stocks to Buy Before They Boom
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
Executives Buy Around $141M Of 4 Stocks
May 10, 2022
Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades.
Via
Benzinga
81 Biggest Movers From Yesterday
May 05, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
May 04, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after...
Via
Benzinga
Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher
May 03, 2022
U.S. stocks traded slightly higher toward the end of trading on Tuesday.
Via
Benzinga
80 Biggest Movers From Yesterday
May 04, 2022
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 03, 2022
Via
Benzinga
Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge
May 03, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.
Via
Benzinga
41 Stocks Moving In Tuesday's Mid-Day Session
May 03, 2022
Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET
April 21, 2022
Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.